Breaking News

ITM Licenses Merck KGaA’s Folate-Based Radiotheranostics

Gains exclusive license for radiolabeled folate derivatives for therapeutic and diagnostic applications against malignant tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, has executed its license agreement with the life science business of Merck KGaA, Darmstadt, Germany, to obtain a worldwide exclusive license for the clinical development and commercialization of radiolabeled folate derivatives for therapeutic and diagnostic applications against folate-receptor-positive malignant tumors.    Under the terms of the agreement, the company will supply ITM with its folate precursors for...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters